Monalisa Hard — Hy-BRID HA Filler for Nasolabial Folds & Lip Augmentation (600µm)

Monalisa Hard is GENOSS’s deeper variant — 24 mg/mL cross-linked HA + 0.3% lidocaine with 600µm particle size via Hy-BRID technology. Engineered for mid-to-deep dermal placement targeting nasolabial folds, lip augmentation, and perilabial wrinkle correction. The larger particle size supports moderate structural fill while preserving Hy-BRID’s smooth monophasic flow.

Monalisa Hard with Lidocaine is manufactured by GENOSS Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2007. The product is part of the Monalisa dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001.

Monalisa Hard with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using GENOSS Co. Ltd.’s Hy-BRID Cross-Linking Technology (600µm particles) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per GENOSS Co. Ltd.’s clinical data, Monalisa Hard with Lidocaine delivers Up to 6 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid to deep dermis placement typically delivers the longer end of the duration range.

Monalisa Hard with Lidocaine is engineered for mid to deep dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Monalisa Hard with Lidocaine regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Monalisa Hard with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Monalisa Hard with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Monalisa Hard with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

For deep cheek augmentation requiring sustained structural projection, GENOSS Monalisa Ultra (900µm) is the dedicated variant — its larger particle size and higher Hy-BRID cross-linking density better support subcutaneous and supraperiosteal placement. Monalisa Hard (600µm) is positioned one density level below — best for mid-to-deep dermal work like nasolabial folds, lip augmentation, and perilabial correction. Practitioners may layer Hard in mid-dermis and Ultra in subcutaneous for combined midface protocols.